Obesity Pillars, Journal Year: 2022, Volume and Issue: 4, P. 100042 - 100042
Published: Dec. 1, 2022
The aim of this qualitative study was to identify a practice level model that could explain sustained change in nutritional behavior.
Language: Английский
Obesity Pillars, Journal Year: 2023, Volume and Issue: 6, P. 100065 - 100065
Published: April 20, 2023
This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) provides clinicians an overview of Artificial Intelligence, focused on the management patients with obesity.
Language: Английский
Citations
68
Journal of clinical lipidology, Journal Year: 2024, Volume and Issue: 18(3), P. e320 - e350
Published: April 24, 2024
BACKGROUNDThis joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk.METHODSThis is based upon scientific evidence, perspectives authors, peer OMA NLA leadership.RESULTSAmong individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles.CONCLUSIONSObesity increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. Among patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD. This risk. leadership. particles.
Language: Английский
Citations
27
Obesity Pillars, Journal Year: 2024, Volume and Issue: 10, P. 100108 - 100108
Published: March 12, 2024
This joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk. is based upon scientific evidence, perspectives authors, peer OMA NLA leadership. Among individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles. increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD.
Language: Английский
Citations
19
Obesity Reviews, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 19, 2024
Summary The rapid and widespread clinical adoption of highly effective incretin‐mimetic drugs (IMDs), particularly semaglutide tirzepatide, for the treatment obesity has outpaced updating practice guidelines. Consequently, many patients may be at risk adverse effects uncertain long‐term outcomes related to use these drugs. Of emerging concern is loss skeletal muscle mass function that can accompany substantial weight reduction; such losses lead reduced functional metabolic health, cycling, compromised quality life, other outcomes. Available evidence suggests trial participants receiving IMDs lost 10% or more their during 68‐ 72‐week interventions, approximately equivalent 20 years age‐related loss. ability maintain caloric restriction‐induced reduction influenced by two key factors: nutrition physical exercise. Nutrition therapy should ensure adequate intake absorption high‐quality protein micronutrients, which require oral nutritional supplements. Additionally, concurrent activity, especially resistance training, been shown effectively minimize therapy. All participate in comprehensive programs emphasizing micronutrient intakes, as well preserve function, maximize benefit IMD therapy, potential risks.
Language: Английский
Citations
16
Obesity Pillars, Journal Year: 2023, Volume and Issue: 5, P. 100056 - 100056
Published: Jan. 28, 2023
This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) is intended to provide clinicians an overview of type 2 diabetes mellitus (T2DM), obesity-related cardiometabolic risk factor.
Language: Английский
Citations
32
Obesity Pillars, Journal Year: 2023, Volume and Issue: 8, P. 100083 - 100083
Published: Aug. 7, 2023
This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) provides an overview of the mechanisms and treatment obesity hypertension.
Language: Английский
Citations
18
Clinical Obesity, Journal Year: 2023, Volume and Issue: 13(6)
Published: July 30, 2023
Obesity is becoming recognized as a complex, chronic medical condition. However, the dominant treatment narrative remains that goal weight can be achieved by eating less, moving more using willpower, placing responsibility for change on person with obesity (PwO). This study evaluated impact of revising this narrative, to viewing treatable condition, internalized bias and perceived patient-provider relationship. PwO were recruited into an online in which two videos presented; first showing traditional doctor endorsing eat move approach, second describing After each video participants asked imagine they being treated completed Weight Bias Internalization Scale (WBIS) Patient-Health Care Provider Communication (PHCPCS). A total 61 (52% response rate) protocol. Compared video, revised resulted significant reductions WBIS scores increases PHCPCS was preferred participants. Within context small-scale evidence supports promoting but condition not result personal failure has positive relationship associated bias. need help reframe from legitimate worthy care.
Language: Английский
Citations
13
Obesity Pillars, Journal Year: 2023, Volume and Issue: 7, P. 100070 - 100070
Published: May 18, 2023
Language: Английский
Citations
11
Obesity Pillars, Journal Year: 2025, Volume and Issue: unknown, P. 100172 - 100172
Published: March 1, 2025
This collaboration from the Obesity Medicine Association (OMA) and American College of Osteopathic Family Physicians (ACOFP) examines obesity management a primary care perspective. joint perspective is based upon scientific evidence, clinical experience authors, peer review by OMA ACOFP leadership. The goal to identify answer sentinel questions about perspective, utilizing evidence-based publications, guided expert experience. disease that contributes both biomechanical complications most common cardiometabolic abnormalities encountered in care. Barriers impede optimal patients with include failure recognize as disease, lack accurate diagnosis, insufficient access treatment resources, inadequate training, time, adequate reimbursement adverse impact bias, stigma, discrimination. physicians are often first line healthcare setting. affords early intervention opportunities prevent and/or treat overweight obesity. Patient enhanced when clinicians risks benefits anti-obesity medications bariatric procedures, well long-term follow-up. Practical tools regarding 4 pillars nutrition therapy, physical activity, behavior modification, medical interventions (anti-obesity surgery) may assist improve health lives living
Language: Английский
Citations
0
Obesity Pillars, Journal Year: 2023, Volume and Issue: 7, P. 100076 - 100076
Published: June 13, 2023
A common adiposopathic complication of obesity is type 2 diabetes mellitus. Healthful weight reduction in patients with can improve glucose metabolism and potentially promote remission However, weight-reduction increased adiposity impaired among mellitus compared to without Data for this review were derived from PubMed appliable websites. Among body fat, the mechanisms underlying those are multifactorial, include energy conservation (i.e., improved control reduced glucosuria), hyperinsulinemia (commonly found many mellitus), potential use obesogenic anti-diabetes medications, contributions multiple systems. Other factors age, sex, genetic/epigenetic predisposition, environments. Even though impairs adiposity, clinically meaningful improves sometimes remission. An illustrative approach mitigate due choosing medications that increase insulin sensitivity loss deprioritize exposure gain.
Language: Английский
Citations
10